Aclaris Therapeutics, Inc. $ACRS Stock Sold by BML Capital Management LLC

BML Capital Management LLC trimmed its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 8.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,955,000 shares of the biotechnology company’s stock after selling 1,020,000 shares during the period. Aclaris Therapeutics accounts for about 30.7% of BML Capital Management LLC’s investment portfolio, making the stock its biggest holding. BML Capital Management LLC owned about 7.84% of Aclaris Therapeutics worth $57,623,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently modified their holdings of ACRS. Mirae Asset Global Investments Co. Ltd. bought a new position in Aclaris Therapeutics in the third quarter worth about $40,000. MBE Wealth Management LLC purchased a new stake in Aclaris Therapeutics in the third quarter worth about $53,000. Jefferies Financial Group Inc. purchased a new stake in Aclaris Therapeutics in the second quarter worth about $58,000. Legal & General Group Plc bought a new stake in Aclaris Therapeutics during the 2nd quarter valued at approximately $61,000. Finally, Walleye Capital LLC bought a new stake in Aclaris Therapeutics during the 2nd quarter valued at approximately $104,000. Institutional investors own 98.34% of the company’s stock.

Analyst Ratings Changes

ACRS has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Aclaris Therapeutics in a report on Wednesday, October 28th. Wedbush lowered their target price on Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating for the company in a research note on Wednesday, October 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, September 21st. Craig Hallum set a $9.00 price target on Aclaris Therapeutics in a research report on Wednesday, October 28th. Finally, Wall Street Zen raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Three equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $11.33.

Aclaris Therapeutics Trading Down 2.0%

Aclaris Therapeutics stock opened at $3.92 on Friday. The business’s fifty day simple moving average is $4.43 and its two-hundred day simple moving average is $4.53. Aclaris Therapeutics, Inc. has a 12 month low of $2.25 and a 12 month high of $6.60. The company has a market capitalization of $621.76 million, a price-to-earnings ratio of -6.76 and a beta of 0.96.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.04. The firm had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.27 million. Aclaris Therapeutics had a negative return on equity of 59.19% and a negative net margin of 1,244.09%. On average, equities research analysts predict that Aclaris Therapeutics, Inc. will post -0.56 EPS for the current year.

About Aclaris Therapeutics

Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.